Journal of Gastroenterology and Hepatology (1991) **6**, 631–632

Author index to volume 6

Abe F. 377
Acharya S. K. 368
Ahmad M. 67
Ahmed W-U. 179
Ahuja R. K. 471
Aikat B. K. 359
Akao T. 599
Akbar S. M. F. 71
Akkermans L. M. A. 253
Alam E. 179
Arora A. 368
Arsenault P. A. 325
Asakura H. 49
Axon A. 23, 45, 131

Bando S. 377
Batey R. G. 585
Baxter J. N. 350
Berry M. 368
Bhargava D. K. 471
Bhaskar K. V. S. 359
Bhathal P. S. 61
Bond W. W. 31
Booth C. C. 169
Bosch J. 91
Bottrill P. M. 45
Boyce H. W. 423
Bremner C. G. 1
Brooks P. 442
Bucher N. R. R. 615
Burra P. 570
Burt R. W. 548
Butler R. N. 81

Cameron D. J. S. 355, 450
Campbell P. E. 450
Chang F-Y. 141
Chang T-T. 481
Chao Y. 481
Chapuis P. H. 325
Chen J-S. 505
Cheng J-T. 141
Chesta J. 91
Clevers G. J. 253
Collen M. J. 1
Coverdale S. A. 585
Cowen A. E. 25
Crantock L. 528
Cummins A. G. 53

Dasarathy S. 471
Davidson G. P. 53
Davidson P. M. 450
Dent J. 1
Dent O. 325
Desmet V. J. 563
Ditchfield M. R. 61
Dixon M. 125
Dobbs B. R. 350
Doe W. F. 175, 455
Donlan J. D. 61

Ehata T. 292
Elias E. 570

Farrell G. C. 585
Fettman M. J. 81
Fiatarone J. R. 585
Fielding L. P. 325
Fleisher D. E. 41
Frydman G. M. 461
Fukao K. 363
Fukuda Y. 499
Furukawa M. 392
Furuta S. 383

Gathright B. 325
Gerschwin M. E. 554
Giarelli L. 278
Gibson P. R. 61, 455
Gibson R. N. 61, 423
Gilbert G. L. 450
Goodwin C. S. 235
Gopal Naidu N. R. 359
Goto H. 377
Graham D. Y. 105
Grant D. R. 626
Guan R. 374, 466
Guo R-X. 155

Haggitt R. C. 1
Hall J. 345
Hapel A. J. 455
Hardcastle J. D. 325, 537, 545
Hardikar W. 450
Hasegawa H. 408, 414
Hashizume M. 476
Hassan R. 59
Hasumura Y. 520
Hawkey C. J. 442
Hayashi N. 265
Hermanek P. 325
Hider R. N. 350
Hirano T. 260
Hirashima T. 377
Hirohashi S. 414
Hogan P. G. 455
Horiike N. 71
Hosoda K. 292
Hsia H-C. 145, 481

Ichikawa Y. 283
Ichimiya H. 155
Ihse I. 423
Ikeoka N. 151
Imoto M. 499
Ishikawa A. 363
Iso Y. 476
Iwanaga T. 476
Iwasaki Y. 363

Jass J. R. 325
Jeng J-S. 141
Jeng S-S. 141

Kage M. 603
Kang J. Y. 531
Kato M. 271
Katoh T. 265
Kawada N. 283
Kawano K. 377
Kawarada Y. 400
Keida Y. 595
Kekki M. 244
Ker C-G. 505
Khan A. H. 67
Kikuchi K. 609
Kioka K. 283
Kitano S. 476
Kiyosawa K. 383
Kiyosawa T. 363
Kobayashi K. 151, 283, 485
Koga A. 155
Kohda H. 609
Kojiro M. 278, 603
Korula J. 625
Kosai K-I. 603
Kosuge T. 408, 414
Koyama Y. 499
Koyanagi N. 476
Kronburg O. 552
Kuroki T. 151, 485

LaBrooy J. T. 53
Lafferty K. J. 574
Lai K-H. 141, 145, 481
Langman M. J. S. 442
Laurino L. 278
Leasa D. 626
Lee A. 115
Lee F-Y. 145, 481
Lee K-T. 505
Lee S-D. 141, 145, 481
Lees W. R. 423
Liang X-H. 77
Lin H-C. 145, 481
Lin W-J. 145
Lo K-J. 145, 481
Loncarevic I. F. 77
Lu L-C. 141

Mackay I. R. 289, 554
Makuuchi M. 408
Malcontenti C. 461

Manabe T. 260
Marshall B. J. 121
Matsui H. 599
Matsumoto K. 509
McAlister V. 626
McCauley R. 345
McCulloch R. 345
McDuffie M. 574
McMichael A. J. 81
Melato M. 278
Misiewicz J. J. 207, 252
Miura S. 49
Mizoguchi Y. 283
Mizumoto R. 400
Monna T. 151, 485
Mori S. 377
Moriwaki H. 271, 414
Mubarik A. 67
Murumatsu Y. 414
Musse M. M. 278
Muto Y. 271

Nagy G. S. 175
Nakajima S. 151
Nakamura T. 509
Nakanishi T. 392
Nakano I. 499
Nakano T. 595
Nakata K. 591
Nakayama F. 155, 595
Namiki M. 609
Natori T. 377
Navasa M. 91
Newland R. C. 325
Ng W-W. 141
Nishi F. 165
Nishiguchi S. 151
Noma A. 271

Obata H. 265, 392
O'Brien P. E. 461
Ochi H. 151
Ochi S. 599
O'Grady J. 558
Ohhira M. 609
Ohta Y. 71, 599
Ohtake H. 165
Ohto M. 292
Ohtu K. 599
Okamoto H. 491
Okuda H. 392
Okuda K. 165, 278
Okuno M. 271
Omata M. 292
Onji M. 71, 599
Osada A. 363
Oshibuchi M. 165

Panda S. K. 368
Penney A. G. 461
Penttila I. A. 53
Platell C. 345
Powell L. W. 528
Prentice R. 528
Price A. B. 209
Pritchard P. J. 177

Qureshi H. 59, 179

Raghunath A. S. 91
Robb T. A. 53
Roberts-Thomson I. C. 81

Sallie R. 558
Samuel D. 532
Sandjaja B. 491
Sastrosoewignjo R. I. 491
Satake T. 499
Sato M. 165
Sehgal S. 359
Sekiya C. 609
Serizawa H. 49
Shang Z-H. 155
Sharma M. P. 368
Sheen P-C. 505
Shen K. 155
Shibayama Y. 591
Shimada K. 408
Shimizu M. 159
Shimizu S. 595
Shimizu Y. 485
Shiomi S. 151, 485
Shiraishi K. 599
Silverstein F. 442
Sipponen P. 244
Siurala M. 244
Smith A. L. 450
Smout A. J. P. M. 253
Spechler S. J. 1
St John D. J. B. 538
Strickland R. G. 238
Sugimachi K. 476
Sundaram K. R. 471

Tabata M. 595
Tagaya O. 271
Takahashi Y. 159
Takayama T. 408, 414
Takayasu K. 414
Takei N. 599
Takeuchi J. 520
Tanabe Y. 271
Tanaka E. 363
Tanaka S. 49
Tandon R. K. 37
Tang Z-Y. 77
Tanner A. R. 91
Taoka H. 400
Tashiro H. 49
Tay H. H. 374
Tobe T. 260
Todo S. 155
Triger D. R. 568
Tsai Y-T. 141, 145, 481
Tsay S-H. 141
Tseng H-C. 155
Tsuchiya M. 49
Tsuji K. 363
Tytgat G. N. J. 103, 139, 223

Ueda T. 151, 609
Uehara A. 609
Umeda M. 599

van der Schee E. J. 253
van Sonnenburg E. 423

Wada H. 476
Wang S-S. 145, 481
Wang Y. 574
Wee A. 466
Williams R. 558
Wu C-C. 505
Wu T-C. 141

Yamaga H. 476
Yamamoto J. 414
Yamamoto S. 283
Yamamoto Y. 363
Yamasaki S. 408, 414
Yamauchi K. 265
Yano Y. 599
Yap I. 374, 466
Yeomans N. D. 177, 442
Yokosuka O. 292
Yonemoto K. 377
Yoshida J. 414
Yoshida N. 609
Yoshioka M. 49

Zanconati F. 278
Zuberi S. J. 59, 179

Journal of Gastroenterology and Hepatology (1991) **6**, 633–638

Subject index to volume 6

abdominal surgery; myo-electrical and motor activity after 253
abdominal ultrasound; detecting abnormalities in Japanese adults 165
abscess; fatal amoebic liver 67
abstracts
  APASL 1990 meeting, Jakarta 183, 297
  Second International Symposium on Primary Biliary Cirrhosis 554
acid
  and non-ulcer dyspepsia pain (Selected Summary) 531
  inhibition or *H. pylori* eradication, in duodenal ulcer treatment 141
activity, myoelectrical and motor; after abdominal surgery 253
adenoma
  colorectal; metabolic phenotypes in (Review) 81
  follow-up surveillance of (Working Party Report) 552
adolescents; with Crohn's disease; gastrointestinal endoscopy in 355
adoptive immunotherapy; proliferation and cytotoxicity of lectin-induced LAK cells 485
aetiology of fulminant viral hepatitis in Japan 159
aflatoxin B-1; liver cysts after pre- and perinatal exposure of rats to 359
alcoholic liver disease; Japanese versus Caucasians (Special Article) 520
alcoholism; epidemiology of primary cancer in non-cirrhotic liver in Italy and Japan 278
alpha-antitrypsin, faecal clearance of in inflammatory bowel disease 49
amino acids
  branched chain; influence on jejunal atrophy in parenteral nutrition 345
  comparison of hepatitis B virus core region residues in carriers and liver patients (Short Communication) 292
amoebic liver abscess, fatal 67
anti-inflammatory drugs and colonic inflammation (Selected Summary) 91
antibody
  hepatitis B core; immunoglobulin G subclasses of, in HBs antigen positive liver disease 71
  hepatitis C virus in endemic HBV and human T cell leukaemia area 599
antigen presentation and effector mechanisms in 'auto-immune' diabetes (PBC Symposium) 574
antipyrine metabolism; in pathogenesis of non-alcoholic steatohepatitis 585
arachidonic acid metabolites; effect on platelet activating factor production in mouse 283
artery, hepatic; in haemodynamics of normal and cirrhotic rat liver 591
Asia, East; hepatolithiasis in 155
Asian Pacific Association for the Study of the Liver; abstracts of 1990 meeting, Jakarta 183, 297
asymptomatic carriers; comparison with liver patients of amino acid residues of hepatitis B virus core region (Short Communication) 292
atrophy, jejunal; influence of glutamine and branched chain amino acids on 345
'auto-immune' diabetes; antigen presentation and effector mechanisms in (PBC Symposium) 574
auto-immune gastritis; the Sydney System (Working Party Report) 238
automatic disinfectors in endoscopy (Working Party Report) 45
autopsy; amoebic liver abscess 67

Barrett's oesophagus (Working Party Report) 1
bile duct carcinoma; CA19–9 and CA125 levels in 505
bilirubin; conjugate forms of in pigment gallstones 595
blood flow in mesenteric veins; significance for oesophageal varices 151
book reviews 95, 181, 419
bowel disease, inflammatory
  faecal clearance of alpha-antitrypsin in 49
  lymphokine-activated killer cells in 455
branched chain amino acids; influence on jejunal atrophy 345

CA125 and CA19–9; levels in cholangitis and bile duct carcinoma 505
caerulein; protection of pancreas by gabexate mesilate in rats with pancreatitis induced by 260
cancer, primary liver; in non-cirrhotic liver in Italy and Japan 278
Captropril; associated with cholestatic jaundice (Case Report) 528
carcinoma
  bile duct; CA19–9 and CA125 levels in 505
  colorectal; metabolic phenotypes in (Review) 81
  hepatocellular
  hepatectomy, embolization or ethanol injection for (Special Article) 408
  oligocentric origin of recurrent and multinodular tumours 77
carriers, HBV; hepatocyte surface antigen expression in 466
Caucasians; comparison with liver disease in Japanese (Special Article) 520
cavernous haemangioma; of liver, growing (Case Report) 414
children
  long-term outcome of hepatitis B infection (Selected Summary) 532
  Helicobacter pylori infection in 450
  with Crohn's disease; gastrointestinal endoscopy in 355
cholangitis; CA19–9 and CA125 levels in 505
cholelithiasis; hepatolithiasis in East Asia 155
cholestatic jaundice; and Captopril therapy (Case Report) 528

chronic active hepatitis; dual colour fluorescein analysis of peripheral blood T cells in 265
chronic gastritis; epidemiology and history of (Working Party Report) 244
chronic liver disease; duplex Doppler ultrasound in patient evaluation 61
cirrhosis
  congestive gastropathy in (Selected Summary) 625
  ventilation/perfusion after liver transplantation in (Selected Summary) 626
  hepatic; effect of thiamine on glucose utilization in 59
  of rat liver; role of hepatic artery in haemodynamics of 591
  isosorbide-5-mononitrate in reducing portal pressure (Selected Summary) 91
  snake skin pattern gastropathy in 145
classification
  of gastritis; Sydney System (Working Party Report) 207
  of cystic liver tumours (Special Article) 400
cleaning and disinfection of endoscopic equipment (Working Party Report) 45
clinical research; history and future prospects in gastroenterology (Special Article) 169
clinicopathological staging, for colorectal cancer; International Documentation System and International Comprehensive Anatomical Terminology (Working Party Report) 325
clinicopathology; of liver involvement in cytomegalovirus in infants 603
co-enzyme; effect of thiamine on glucose utilization in hepatic cirrhosis 59
coeliac disease; small intestine recovery on gluten-free diet 53
colitis, ulcerative; and faecal clearance of alpha-antitrypsin in inflammatory bowel disease 49
colonic inflammation; and anti-inflammatory drugs (Selected Summary) 91
colorectal cancer; clinicopathological staging of (Working Party Report) 325
colorectal neoplasia; and metabolic phenotypes (Review) 81
Comprehensive Anatomical Terminology; for clinicopathological staging of colorectal cancer (Working Party Report) 325
congestive gastropathy in cirrhosis (Selected Summary) 625
core region, of hepatitis B virus; comparison of amino acid residues in carriers and liver patients (Short Communication) 292
Crohn's disease
  faecal clearance of alpha-antitrypsin in 49
  gastrointestinal endoscopy in children and adolescents with 355
cystic liver tumours; new classification of (Special Article) 400
cysts, liver; after prenatal and perinatal exposure to aflatoxin B-1 in rats 359
cytomegalovirus in infants; liver involvement in 603
cytotoxicity of lectin-induced, lymphokine-activated killer cells 485

diagnostic utility of ultrasonography; in hepatic venous outflow tract obstruction 368
disinfection
  and endoscopy (Working Party Report) 23
  microbiology of endoscopic (Working Party Report) 31
Doppler ultrasound; in chronic liver disease and portal hypertension 61
double-blind study; of misoprostol in duodenal ulcer healing (Short Communication) 179
drugs, non-steroidal anti-inflammatory; ulcer associated with (Working Party Report) 442
dual colour fluorescein analysis; of peripheral blood T cells in auto-immune chronic active hepatitis 265
duodenal ulcer
  acid inhibition or *H. pylori* eradication, in medical treatment of 141
  and *H. pylori* (Editorial Comment) 177
  epidemiology and role of *H. pylori* in (Working Party Report) 105
  misoprostol in healing of (Short Communication) 179
  relationship with *H. pylori* and hypergastrinaemia (Selected Summary) 417
dyspepsia, non-ulcer; acid and the pain of (Selected Summary) 531

East Asia; hepatolithiasis in 155
Editorial Comment
  Helicobacter pylori and duodenal ulcer 177
  phenotypes of T lymphocytes 289
  Sydney World Congresses of Gastroenterology 175
electrogastrography; for evaluating stomach activity after abdominal surgery 253
embolization; choice of treatments for small hepatocellular carcinoma (Special Article) 408
endoscopic disinfection
  Working Party Report 23
  and staff safety (Working Party Report) 41
  automatic (Working Party Report) 45
  microbiology of (Working Party Report) 31
  recommendations and practices for (Working Party Report) 37
endoscopic division; of Sydney System for classification of gastritis (Working Party Report) 223
endoscopic sclerotherapy; in management of oesophageal varices 471
endoscopy
  and risk of infection (Working Party Report) 25
  gastrointestinal; in children and adolescents with Crohn's disease 355
endotoxin; and expansion modes of liver macrophages after hepatectomy 499
environment; and primary biliary cirrhosis (PBC Symposium) 568
epidemiology
  and history of chronic gastritis (Working Party Report) 244
  of hepatitis B virus in Indonesia 491
  of hepatolithiasis in East Asia 155
  of *H. pylori* in duodenal ulcer disease (Working Party Report) 105
  of NSAID-associated ulcer (Working Party Report) 442
  of primary cancer in non-cirrhotic liver in Italy and Japan 278

equipment; cleaning of endoscopic (Working Party Report) 45
eradication; of *H. pylori* in duodenal ulcer treatment 141
ethanol
injection; choice of treatments for small hepatocellular carcinoma (Special Article) 408
injury to gastric mucosa 461
ethanolamine oleate; versus sodium morrhuate for sclerotherapy of oesophageal varices 476
exocrine pancrease; protection of by gabexate mesilate in rats with acute pancreatitis 260
extrahepatic portal venous obstruction; endoscopic sclerotherapy in management of 471

faecal clearance; of alpha-antitrypsin in inflammatory bowel disease 49
familial screening; for colorectal neoplasia (Working Party Report) 548
flexible endoscopes; cleaning and disinfection of (Working Party Report) 45
fulminant viral hepatitis; aetiology of, in Japan 159

gabexate mesilate (FOY); protection of pancreas in rats with acute pancreatitis 260
gallstones, pigment; conjugate forms of bilirubin in formation of 595
gastric mucosa
changes in, in rats with portal hypertension 350
ethanol injury to 461
gastritis
auto-immune (Working Party Report) 238
Helicobacter pylori infection in children 450
microbial (Working Party Report) 235
Sydney System for classification of (Working Party Report) 207
gastroenterology; history and future of clinical research in (Special Article) 169
gastrography; to evaluate stomach activity after abdominal surgery 253
gastrointestinal endoscopy; in children and adolescents with Crohn's disease 355
gastrointestinal tumours; role of imaging in non-operative staging of (Working Party Report) 423
gastropathy
congestive, in cirrhosis (Selected Summary) 625
snake skin pattern; in cirrhosis 145
genetics; metabolic phenotypes and colorectal neoplasia (Review) 81
glucose utilization, in hepatic cirrhosis; effect of thiamine on 59
glutamine; influence on jejunal atrophy in parenteral nutrition 345
gluten-free diet; small intestine recovery in coeliac disease 53

haemodynamics of rat liver; role of hepatic artery in 591
haemorrhage, oesophageal variceal; terlipressin for 481
HBs; immunoglobulin G subclasses of antibodies in antigen-positive liver disease 71
Helicobacter pylori
and duodenal ulcer (Editorial Comment) 177
and peptic ulcer disease (Working Party Report) 103
as causal agent in peptic ulcer disease (Working Party Report) 139
effect of therapy on peptic ulcer disease (Working Party Report) 131
epidemiology and role in duodenal ulcer disease (Working Party Report) 105
eradication or acid inhibition, in duodenal ulcer treatment 141
histopathology in peptic ulceration (Working Party Report) 125
infection in children 450
relationship with hypergastrinaemia and duodenal ulcer (Selected Summary) 417
virulence and pathogenicity in peptic ulcer disease (Working Party Report) 121
hepatectomy; effect of endotoxin on expansion modes of liver macrophages after 499
hepatic artery; in haemodynamics of normal and cirrhotic rat liver 591
hepatic cirrhosis; effect of thiamine on glucose utilization in 59
hepatic fibrosis; immunoreactive prolyl hydroxylase levels in rats 271
hepatic functional volume; trimethadione tolerance test for assessment of, in rats 363
hepatic sinusoidal epithelial cells; effect of arachidonic acid metabolites on platelet activating factor production by 283
hepatic tumour, transplanted; effects of stress on growth 609
hepatic venous outflow tract obstruction; diagnostic utility of ultrasonography 368
hepatitis
chronic active; dual colour fluorescein analysis of peripheral blood T cells in 265
fulminant viral; aetiology of, in Japan 159
hepatitis B core antibody; immunoglobulin G subclasses in HBs antigen positive liver disease 71
hepatitis B virus
analysis of structure, in hepatocellular carcinoma 77
half- versus full-dose recombinant DNA vaccine 374
HCV antibody in area endemic for 599
hepatocyte surface antigen expression in HBV carriers 466
in Indonesia; molecular epidemiology of 491
long-term outcome of childhood infection (Selected Summary) 532
hepatitis C
in Japan (Review) 383
antibody in endemic HBV and human T cell leukaemia area 599
hepatocellular carcinoma
and vitamin K-dependent proteins (Review) 392
hepatectomy, embolization or ethanl injection for (Special Article) 408
oligocentric origin of recurrent and multinodular tumours 77
hepatocyte growth factor; in liver regeneration (Review) 509
hepatocyte hepatitis B; surface antigen expression in HBV carriers 466
hepatolithiais; in East Asia 155
high-dose terlipressin; for oesophageal variceal haemorrhage 481

histological division; of Sydney System for classification of gastritis (Working Party Report) 209
histopathology; of *H. pylori* in peptic ulcer disease (Working Party Report) 125
history; and future of clinical research in gastroenterology (Special Article) 169
human T cell leukaemia; HCV antibody in area endemic for 599
hypergastrinaemia; relationship with *H. pylori* and duodenal ulcer (Selected Summary) 417
hyperglycaemia; effect of thiamine on glucose utilization in hepatic cirrhosis 59
hypertension, portal
duplex Doppler ultrasound in patient evaluation 61
isosorbide-5-mononitrate in reducing portal pressure (Selected Summary) 91
hypertriglyceridaemia; in pathogenesis of non-alcoholic steatohepatitis 585

imaging; role in non-operative staging of gastrointestinal tumours (Working Party Report) 423
immune responses; effects of stress on 609
immunoglobulin G; subclasses of hepatitis B core antibodies in HBs antigen positive liver disease 71
immunoreactive prolyl hydroxylase; serum and hepatic levels in hepatic fibrosis in rats 271
impedance gastrography; to evaluate stomach activity after abdominal surgery 253
Indonesia; molecular epidemiology of hepatitis B virus in 491
infants; liver involvement in cytomegalovirus in 603
infection
clinical risk of, in endoscopy (Working Party Report) 25
Helicobacter pylori; in children 450
hepatitis B; long-term outcome of childhood infection (Selected Summary) 532
inflammatory bowel disease
faecal clearance of alpha-antitrypsin in 49
lymphokine-activated killer cells in 455
interleukin-1; effect on platelet activating factor production in mouse 283
International Documentation System; for clinicopathological staging of colorectal cancer (Working Party Report) 325
intestinal permeability; in recovery from coeliac disease 53
isosorbide-5-mononitrate; in reducing portal pressure (Selected Summary) 91

Japan
aetiology of fulminant viral hepatitis in 159
detecting abnormalities by abdominal ultrasound 165
hepatitis C in (Review) 383
hepatolithiasis in 155
Japanese; comparison with liver disease in Caucasians (Special Article) 520
jaundice, cholestatic; associated with Captopril therapy (Case Report) 528
jejunal atrophy, in parenteral nutrition; influence of glutamine and branched chain amino acids on 345

killer cells, lymphokine-activated
cytoxicity and proliferation of 485
in inflammatory bowel disease 455

LEC/Otk rats; spontaneous hepatic injury in 377
leukaemia, human T cell; HCV antibody in area endemic for 599
ligamentum teres; duplex Doppler ultrasound of 61
liver
cancer, primary; in non-cirrhotic liver in Italy and Japan 278
cirrhosis; endoscopic sclerotherapy in management of 471
cysts; after pre- and perinatal exposure to aflatoxin B-1 in rats 359
disease, alcoholic; comparison of Japanese and Caucasians (Special Article) 520
fatal amoebic abscess 67
growing cavernous haemangioma (Case Report) 414
involvement in cytomegalovirus in infants 603
macrophages; effect of endotoxin on expansion modes after hepatectomy 499
pathology; and hepatocyte hepatitis B surface antigen expression in HBV carriers 466
regeneration
hepatocyte growth factor in (Review) 509
Review 615
transplantation; ventilation/perfusion after (Selected Summary) 626
tumour, cystic malignant; new classification of (Special Article) 400
transplanted; effects of stress on growth of 609
Liver Cancer Society of Japan; classification of cases presented at the 26th annual meeting (Special Article) 400
low-dose terlipressin; for oesophageal variceal haemorrhage 481
lymphokine-activated killer cells
cytotoxicity and proliferation of lectin-induced 485
in inflammatory bowel disease 455

macrophages, liver; effect of endotoxin on expansion modes after hepatectomy 499
malnutrition, protein-calorie; and faecal alpha-antitrypsin clearance in inflammatory bowel disease 49
mesenteric veins; significance of blood flow for oesophageal varices 151
metabolic phenotypes; and colorectal neoplasia (Review) 81
microbial gastritis; the Sydney System (Working Party Report) 235
microbiology
in disinfection and endoscopy (Working Party Report) 31
of *H. pylori* in peptic ulcer disease (Working Party Report) 115
misoprostol; in duodenal ulcer healing (Short Communication) 179
molecular epidemiology; of hepatitis B virus in Indonesia 491
motor and myo-electrical activity; of the stomach after abdominal surgery 253
mucosa, gastric; changes in, in rats with portal hypertension 350
multicentre study; of aetiology of fulminant viral hepatitis in Japan 159

neoplasia, colorectal, and metabolic phenotypes (Review) 81

neoplastic growth; cavernous haemangioma of liver (Case Report) 414
non-alcoholic steatohepatitis; pathogenesis of 585
non-cirrhotic liver cancer; epidemiology in Italy and Japan 278
non-cirrhotic portal fibrosis; endoscopic sclerotherapy in management of 471
non-steroidal anti-inflammatory drugs
and colonic inflammation (Selected Summary) 91
-associated ulcer; epidemiology, causation and treatment (Working Party Report) 442
non-ulcer dyspespia; acid and the pain of (Selected Summary)

oesophageal varices
endoscopic sclerotherapy in management of 471
ethanolamine oleate versus sodium morrhuate for haemorrhage; terlipressin for 481
sclerotherapy of 476
significance of mesenteric blood flow for formation of 151
oesophagus, Barrett's (Working Party Report) 1

pancreatitis, acute; protection of exocrine pancreas in rats by gabexate mesilate 260
parenteral nutrition; influence of glutamine and branched chain amino acids on jejunal atrophy in 345
pathogenicity; of *H. pylori* in peptic ulcer disease (Working Party Report) 121
pathology; of spontaneous hepatic injury in rats 377
peptic ulcer disease; *Helicobacter pylori* as causal agent (Working Party Report) 103
perfusion, after liver transplantation (Selected Summary) 626
phenotypes; of T lymphocytes (Editorial Comment) 289
pigment stones; conjugate forms of bilirubin in formation of 595
platelet activating factor; effect of arachidonic acid metabolites on production of, in mouse 283
portal circulation; significance of mesenteric flow in formation of oesophageal varices 151
portal fibrosis, non-cirrhotic, and venous obstruction; endoscopic sclerotherapy in management of 471
portal hypertension
changes in gastric mucosa in rats with 350
duplex Doppler ultrasound in patient evaluation 61
isosorbide-5-mononitrate in reducing portal pressure (Selected Summary) 91
portal pressure; and snake skin pattern gastropathy in cirrhosis 145
portal vein; duplex Doppler ultrasound of 61
practices and recommendations for endoscopic disinfection (Working Party Report) 37
primary biliary cirrhosis
abstracts (PBC Symposium) 580
can the pathologist forecast causation of (PBC Symposium) 563
environmental contribution (PBC Symposium) 568
overview of PBC Symposium 554
symptomatic treatment of (PBC Symposium) 570
transplantation in (PBC Symposium) 558
primary liver cancer; in non-cirrhotic liver in Italy and Japan 278
prognostic index; International Documentation System and Comprehensive Anatomical Terminology for staging of colorectal cancer (Working Party Report) 325
prolyl hydroxylase, immunoreactive; serum and hepatic levels in hepatic fibrosis in rats 271
prostaglandin; misoprostol in duodenal ulcer healing (Short Communication) 179
protein-calorie malnutrition; and faecal clearance of alpha-antitrypsin clearance in inflammatory bowel disease 49
proteins, vitamin K-dependent; and hepatocellular carcinoma (Review) 392

rat
changes in gastric mucosa, in portal hypertension 350
cirrhotic and normal liver; role of hepatic artery in haemodynamics of 591
immunoreactive prolyl hydroxylase levels in hepatic fibrosis in 271
liver cysts after pre- and perinatal exposure of rats to aflatoxin B-1 359
spontaneous hepatic injury in 377
trimethadione tolerance test for assessment of liver function in 363
recombinant DNA vaccine; half- versus full-dose for hepatitis B 374
recommendations and practices for endoscopic disinfection (Working Party Report) 37
regeneration, liver
hepatocyte growth factor in (Review) 509
Review 615

sclerotherapy of oesophageal varices
efficacy of endoscopic 471
ethanolamine oleate versus sodium morrhuate for 476
screening
abdominal ultrasound in Japanese adults 165
for colorectal neoplasia
average risk individuals (Working Party Report) 545
familial (Working Party Report) 548
tests (Working Party Report) 538
Working Party Report 537
for hepatic venous outflow tract obstruction; role of ultrasonography in 368
Second International Symposium on Primary Biliary Cirrhosis 554
Singapore; hepatocyte hepatitis B surface antigen expression in HBV carriers in 466
small bowel morphology; in small intestine recovery from coeliac disease 53
small intestine; recovery in coeliac disease 53
snake skin pattern gastropathy; in cirrhosis 145
sodium morrhuate; versus ethanolamine oleate for sclerotherapy of oesophageal varices 476
spontaneous hepatic injury in rats 377
staff safety; in endoscopic disinfection (Working Party Report) 41
staging, of gastrointestinal tumours; role of imaging in (Working Party Report) 423
steatohepatitis, non-alcoholic; pathogenesis of 585
stomach; myo-electrical and motor activity after abdominal surgery 253
stress; effects on transplanted hepatic tumour growth and immune responses 609

structure; of hepatitis B virus in hepatocellular carcinoma 77
surface antigen, hepatocyte hepatitis B; expression in HBV carriers 466
surveillance, follow-up; of adenoma patients (Working Party Report) 552
Sydney System; for classification of gastritis (Working Party Report) 207
symptomatic treatment; of primary biliary cirrhosis (PBC Symposium) 570

T cell
activity in small intestine recovery from coeliac disease 53
peripheral blood; dual colour fluorescein analysis of in auto-immune chronic active hepatitis 265
functional phenotypes of (Editorial Comment) 289
terlipressin; for oesophageal variceal haemorrhage 481
therapy
Captopril; associated with cholestatic jaundice (Case Report) 528
for *H. pylori* in peptic ulcer disease (Working Party Report) 131
thiamine; effect on glucose utilization in hepatic cirrhosis 59
time; as a factor in ethanol injury to gastric mucosa 461
trimethadione tolerance test; for assessment of liver function in rats 363
tumour
cystic liver; new classification of (Special Article) 400
gastrointestinal; role of imaging in staging of (Working Party Report) 423
markers; CA19–9 and CA125 levels in cholangitis and bile duct carcinoma 505
oligocentric origin of, in hepatocellular carcinoma 77
transplanted hepatic; effects of stress on growth 609

ulcer, associated with NSAID; epidemiology, causation and treatment (Working Party Report) 442
ulcerative colitis; faecal clearance of alpha-antitrypsin in 49
ultrasonography; diagnostic utility for hepatic venous outflow tract obstruction 368
ultrasound
abdominal; in Japanese adults 165
duplex Doppler; in chronic liver disease and portal hypertension 61

vaccine, recombinant DNA hepatitis B; half- versus full-dose 374
varices, oesophageal
significance of mesenteric blood flow for formation of 151
terlipressin for haemorrhage of 481
ventilation, after liver transplantation (Selected Summary) 626
viral hepatitis, fulminant; aetiology of, in Japan 159
viral replication; and hepatocyte hepatitis B surface antigen expression in HBV carriers 466
virulence; of *H. pylori* in peptic ulcer disease (Working Party Report) 121
vitamin K-dependent proteins; and hepatocellular carcinoma (Review) 392

Working Party Reports to the World Congresses of Gastroenterology, Sydney 1990
Barrett's oesophagus 1
clinicopathological staging for colorectal cancer 325
disinfection and endoscopy 23
Editorial Comment 175
Helicobacter pylori and peptic ulcer disease 103
role of imaging in the non-operative staging of gastrointestinal tumours 423
NSAID-associated ulcer epidemiology, causation and treatment 442
screening for colorectal neoplasia 537
Sydney System for classification of gastritis 207
World Congresses of Gastroenterology, Sydney 1990 — see *Working Party Reports*